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Approximately 13% of the pediatric population suffer from atopic dermatitis (AD) or eczema 
(Silverberg & Simpson, 2014). Eczema is a complex and costly managed disease.  There is a 
need to improve caregiver knowledge and to maintain and control exacerbations as national 
prevalence increases in the United States.  Literature supports utilization of a written Eczema 
Action Plan (EAP) to improve caregiver self-efficacy of eczema management.  An evidence-
based practice project was conducted in a primary care pediatric practice implementing a written 
EAP for mild to severely diagnosed patients ranging from 4 months to 17 years of age. The 
practice intervention included providing each caregiver with an individualized written EAP 
developed by the American Academy of Dermatology (AAD), an eczema patient education 
handout by The Society for Pediatric Dermatology, and a list of over-the-counter products 
endorsed by the National Eczema Association.  Thirty caregivers were recruited for this pilot and 
22 participants completed the project. The validated Patient Oriented Eczema Measurement for 
children (POEM) and the Parental Self-Efficacy Care Index (PASECI) tools were completed by 
caregivers pre-intervention and again between 6- and 8-weeks post-intervention. Eczema 
severity decreased by approximately 65% and caregiver self-efficacy increased with an average 
score of 8.11/10 utilizing the PASECI.  A written EAP is easily adaptable in the primary care 
setting closing communication barriers between caregiver and provider. Utilization of a written 
EAP establishes best care practice congruent with the American Academy of Pediatrics (AAP) 
clinical guidelines. Potential benefits include reduction in follow-up visits, treatment costs, 
improvement in referral identification, and increased caregiver and patient satisfaction. 
Keywords: eczema action plan, childhood eczema, caregiver self-efficacy, POEM, 
PASECI 




Background and Evidence for Clinical Problem 
Eczema primarily affects children. Eighty-five percent of children diagnosed with eczema 
have an onset of the disease before 5 years of age  (Tollefson, Bruckner, & Dermatology, 2014).  
The condition can range in severity from mild to severe forms causing pruritus, pain, and an 
increased risk for infections.  Managing eczema is a challenge for parents because skincare is 
complex and must include specific treatment for flare-ups and long-term maintenance (Shi, 
Shivani, Lee, Armstrong, & Lio, 2013).   Lack of adherence to complex treatment regimens is a 
common cause of treatment failure in many long-term conditions in children including eczema, 
asthma and diabetes (Waldecker, Malpass, King, & Ridd, 2013). Ineffective management of 
childhood eczema stems from lack of parental knowledge and self-efficacy regarding the 
condition, skincare maintenance, and treatment of acute exacerbations.  For the care in 
management of AD for children, the AAD insists the use of written action plans as an 
educational intervention to reinforce parental education and improve AD severity (Sidbury, 
Bergman, Copper, Silverman, & Berger, 2014). 
Eczema can negatively affect the quality of life for patients and their family physically 
and emotionally.  An informal systematic review found itching and scratching affected the 
quality of life in children the most in addition to lack of sleep, pain, and restrictions in physical 
and social activities.  Family members were affected by symptoms of itching and scratching due 
to lack of sleep and feelings of helpless emotions seeing their children suffer.  A systematic 
review concluded that when AD severity increases, quality of life decreases as well.  Studies 
revealed generalized eczema is responsible for the second greatest impact affecting quality of life 
following cerebral palsy (Drucker et al., 2017).  The impact of eczema on quality of life of the 
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family is not limited to the United States.  In broader spectrum, the results of a current cross-
sectional study of 110 children in Malaysia shows AD negatively affects the quality of life for 
patients as well as their family members evidenced by the Dermatitis Family Impact score 
(Ghani, Noor, Muhamad, & Ismail, 2013).   
Childhood Eczema in the United States and California 
The prevalence of childhood eczema is increasing in the United States.  A most recent 
study analyzed data from the 2007 National Survey of Children’s Health.  A national sample of 
92,642 children ages 0 to17 years revealed 12.9% had been diagnosed with childhood eczema 
(Silverberg & Simpson, 2014) as opposed to 10.7% in a previous study conducted 3 years prior 
(Shaw, Currie, Koudelka, & Simpson, 2011).  This increase indicates a need for quality 
improvement in the management of eczema by primary care providers and caregivers.  Of the 
12.9% of diagnosed patients, 67% had mild disease, 26% have moderate disease, and 7% have a 
severe form of eczema (Silverberg & Simpson, 2014).   Furthermore, the rate of severe 
childhood eczema in the state of California is 5.9% (Silverberg & Simpson, 2014).   
Expenditures for AD add to the burden for families. The average cost to manage AD one 
month prior to seeing a provider is $274 in the United States (Filanovsky et al., 2016).  The 
national estimated annual costs to manage eczema is $5.297 billion dollars (Drucker et al., 2017). 
Improved management of mild to moderate eczema in pediatric primary care can potentially 
prevent disease progression and improve long-term outcomes.  
Childhood Eczema Management in a Pediatric Primary Care Clinic 
 Eczema is commonly treated by providers in pediatric primary care with topical 
emollients and corticosteroids.  In some cases, the condition is poorly managed by caregivers and 
the severity of eczema worsens causing physical discomfort and emotional stress to the child and 
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family.  Successful management of this condition requires parents to have a knowledge of 
eczema, triggers, a prescribed skincare regimen, and how to manage flare-ups. Common practice 
to educate parents primarily includes verbal instruction without the use of a written plan.  Verbal 
instructions can be vague leaving parents feeling inadequate to care for their child’s eczema.  
The AAP supports the use of an EAP to provide comprehensive education for parents managing 
the symptoms of childhood eczema.  Although clinical guidelines have been published by the 
AAP to implement EAPs, variability exists in clinical practices (Tollefson & Bruckner, 2014).  
Gaps in parental education have led to different expected outcomes between parents and 
providers.  A qualitative study at the University of Bristol determined the challenges of 
managing eczema included a lack of support and information provided to parents resulting in 
differing views about its causes and management.  Some parents were looking for a cure due to a 
root cause such as an allergy.  Primary care providers viewed eczema as a chronic condition 
recommending emollients to prevent exacerbations (Powell, Roux, Banks, & Ridd, 2018).  
Additionally, another qualitative study demonstrated many families were unaware of the reason 
behind why emollients were even suggested (Santer et al., 2013).   
Poorly managed eczema was reported by the physician and observed by the Doctor of 
Nursing (DNP) candidate at the clinical site of this pilot study.  Due to a lack of an electronic 
medical records (EMR) system, it was difficult to track the prevalence of eczema in the practice. 
The DNP candidate blindly reviewed 100 paper health records to determine the prevalence of 
eczema in the practice.  Forty-one percent had documentation of an eczema diagnosis during 
various time periods of care indicating a strong need for caregiver intervention.   
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Proposed Evidence-Based Solutions 
A literary search was conducted using PubMed, CINAHL Plus, Health and Psychosocial 
Instruments, and Google Scholar.  Key words included eczema action plan, pediatric atopic 
dermatitis, self-management of eczema, parental education, parental self-efficacy, and eczema 
severity index.  The search yielded 3592 articles and was narrowed to 32 pertinent articles 
mostly published less than 5 years ago.  Of the 32 articles reviewed, 26 articles were used in this 
final pilot project.   
 The utilization of a written EAP in conjunction with verbal instruction increases parental 
confidence level when managing daily skincare of mild to severe symptoms of eczema.  A recent 
randomized controlled trial included parents of 88 children diagnosed with AD ranging in age 
from 1 month to 12 years found the use of an EAP over a span of 3 months demonstrated 
significant improvement in parental confidence through quality of life measures.  Improvement 
was demonstrated in domains that included,  “I feel certain about what to do when my child’s 
skin is getting worse,” (P=.003), “know names of creams to use on my child’s skin,” (P=.016), 
and “feel helpless about my child’s skin condition,” (P=.034) (Gilliam, Madden, Sendowski, 
Mioduszewski, & Duderstadt, 2016).   
Another randomized controlled trial included a combination of 37 AD patients and 
caregivers of children less than 18 years of age showing how an EAP combined with verbal 
instruction significantly improved multiple areas of eczema management.  Some of the domains 
demonstrating improvement included daily treatment plan (P<.01), adjust treatment based on AD 
severity (P<.001), remission recognition (P<.001), and comfort with treatment plan (P<.01) (Shi 
et al., 2013).  Recent evidence validated EAPs are useful and can be applied to primary care 
practice. 
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 The AAP provided a sample EAP for the management of AD within their most recent 
atopic dermatitis guidelines (Tollefson et al., 2014).  It includes a step-by-step process of daily 
skincare maintenance, application of anti-inflammatory medications, itch control, and 
recognition of exacerbations.  There are currently no guidelines that standardizes EAP format or 
content.  The International Consensus Conference on AD II (ICCAD II) suggested EAPs follow 
specific criteria that includes written instructions remain with the patient, has a step-wise 
treatment approach based on severity of symptoms, and content should be validated by patients 
and caregivers (Sauder, McEvoy, & Ramien, 2016).   
Use of a 3-step EAP format was preferred by parents and may increase confidence in the 
knowledge of skincare management according to a qualitative study from the University of 
Bristol.  Forty-one participants including healthcare professionals from multiple disciplines, 
parents, and stakeholders provided input to create an eczema written action plan (EWAP) for 
children.  They designed an EWAP based on clear instructions presented in a step-by-step 
process with color and pictures to engage children and aid in communication and comprehension 
for parents.  Generalized information about eczema including the condition itself, triggers, tips 
for moisturizing, flare-up recognition, and additional links to resources was included in the final 
EWAP design at the request of the participants (Powell et al., 2018).  The EWAP format and 
content closely mimics criteria set forth by the ICCAD II, however it has not been validated in 
clinical practice. 
Establishing a clear understanding of eczema helps parents and providers share the same 
treatment goals.  In the University of Bristol study, general practitioners identified conflicting 
treatment goals between providers and parents as a barrier to successfully treating and managing 
eczema.  The participants of the study, including parents and general practitioners, preferred 
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receiving and distributing general eczema information including the rationale for using 
emollients (Powell et al., 2018).   In addition, previous research showed when practitioners 
established a strong relationship with parents by providing a clear explanation of eczema, 
adherence to treatment was more likely (Santer et al., 2013).  It is important to provide parents 
with generalized eczema information to create a better understanding of the condition, the course 
of treatment, and provider expectations. 
Providers who take time to explain treatment plans to parents increase parental 
comprehension of skin management.  In order to close the communication gap between providers 
and caregivers of pediatric patients, practitioners need to be willing to take the time to explain 
treatment plans.  This includes highlighting the disease process and explaining proper medication 
administration.  Written EAPs should be explained carefully in order to engage caregivers in 
various aspects of skincare management.  This principle of shared decision making can result in 
improved long-term outcomes (Levy, 2013). 
There is currently no standardized written action plan design that has been clinically 
tested for effectiveness with the exception of a few studies where EAPs were independently 
created.  Currently a multi-disciplinary group from the Children’s Hospital of Eastern Ontario in 
Ottawa, Canada are in the process of developing and clinically testing a written action plan 
(Innes-Leroux, 2016).  Currently no validated action plan has been disseminated.  The AAD and 
The Society for Pediatric Dermatology created a pediatric EAP and a patient education handout 
of general eczema information respectively (“How will I know what to do to control the 
eczema?,” 2018; “Patient Handouts,” 2018.).  These resources are available for public use 
without cost.  The formats are congruent with that of the EWAP and the ICCAD II criteria and 
therefore were utilized in this pilot study.   
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Description of EBP Project 
This pilot project was conducted in a private pediatric clinic with one physician, the DNP 
candidate, three nursing assistants, and an office manager.  Patients diagnosed with eczema were 
identified by the physician and DNP candidate during well-check and ill visits.  Caregiver 
participation was voluntary.  Prior to implementation, parents completed a demographics 
questionnaire (see Appendix A), the validated POEM (see Appendix B) designed for children to 
rate eczema severity, and the validated PASECI (see Appendix C) to measure caregiver self-
confidence (Charman, Venn, & Williams, 2004; Ersser et al., 2015).   The DNP candidate then 
implemented an individualized written EAP designed by the AAD and individualized it to each 
patient based on the physician’s orders (see Appendix D).  In addition, caregivers received an 
eczema patient education handout published by the Pediatric Society of Dermatology (see 
Appendix E) and a list of National Eczema Association approved over-the-counter products 
including moisturizers and cleansers (see Appendix F).  Caregiver comprehension of the EAP 
was measured immediately post intervention using a Likert-like survey question (see Appendix 
G).  
The POEM and PASECI questionnaire were completed again between 6- and 9-weeks 
post EAP intervention via Google Forms. The average response time was 7.14 weeks.  A $20 gift 
card incentive was offered to each participant for completion of the questionnaires after a 6-week 
timeframe (see Appendix H).  A systematic review concluded the use of moisturizers in patients 
who had mild to moderate eczema effectively treated eczema within a 6 week to 6 month 
timeframe justifying the follow-up time for this pilot project (Becker & Rensberry, 2018).  
Documentation of EAP implementation and the date of issue to caregivers was completed 
in each patient record by the DNP candidate.  The EAP will remain an important part of the 
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patients’ course of eczema care and management. The primary care provider will be able to 
obtain an understanding of caregiver eczema health literacy and guide the decision-making 
process to modify the EAP or conduct a referral to dermatology in the event eczema is not 
controlled in the future. 
Measurements 
The POEM designed for children was utilized to obtain the extent of eczema severity as 
reported by the caregiver of the child.  The POEM consists of seven questions of equal weight.  
All seven questions ask the caregiver to describe how often eczema symptoms are experienced 
from zero days to every day.  POEM scores were calculated by adding up points for all seven 
questions.  Each question was worth zero to four points dependent on how often symptoms 
presented within the last week for a maximum score of 28.  The outcome of the total score 
helped patients and clinicians identify the severity of eczema from clear or almost clear to very 
severe eczema.  The POEM is validated and suitable for use in outpatient clinic settings 
(Charman et al., 2004).  It is copyrighted by the University of Nottingham and free for clinicians 
to use. The English version of the POEM was utilized in this project.    
The POEM instrument has been utilized in current studies.   In 2015, a randomized 
clinical trial compared the effectiveness of direct verses online access for eczema follow-up care 
for pediatric and adult patients. Additionally, it was used in this trial to assess disease severity.  
Results indicated direct and online access to care were equivalent in clinical outcomes 
(Armstrong et al., 2015).  In 2017, a randomized control trial used the POEM and demonstrated 
children in ambulatory care with mild eczema did not clinically benefit from oral and topical 
antibiotics in addition to topical emollients and corticosteroids  (Francis et al., 2017).   
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The PASECI was utilized to examine caregiver self-efficacy in eczema management.  It 
is validated and reliable with high consistency in all domains (Cronbach’s  > 0.87) (Ersser et 
al., 2015).  The instrument is organized into four sections.  Sections include parental confidence 
measurements in managing medication, managing symptoms, communicating with health care 
professionals, and managing personal challenges.  There are 29 total questions and confidence 
levels are measured using a Likert-like scale from 0 (cannot do at all) to 10 (highly certain can 
do).  For the purposes of this project, only caregiver ability to manage eczema and symptoms 
were examined.  The seven parental self-efficacy category measurements included caregiver 
ability to apply moisturizers, chose appropriate moisturizers, avoid triggers, chose appropriate 
medication, manage symptoms, recognize infection and properly use topical steroids. Currently, 
only an English and Korean version of the PASECI have been validated (Lee, Son, Kim, Han, & 
Noh, 2016).  The PASECI instrument has not been found in recent eczema management studies.   
Anticipated Project Outcomes 
Three short-term goals were established for this project.  The first goal was to obtain 
parent comprehension of the implemented EAP with a reported average score of 8 of 10 using a 
Likert-like survey question.  A score of 0 equated to no understanding and score of 10 equated to 
full understanding.  Parental comprehension was rated immediately after the implementation of 
the EAP to ensure successful parental education.  The second goal was for parents to report 
reduced eczema severity post intervention by an average of 5 points utilizing the validated 
POEM tool.  The POEM tool was completed by parents at the initial encounter and again at 6 
weeks.  The third goal was for parents to score an average of 8 of 10 for self-efficacy using the 
PASECI post EAP intervention.  Similarly, this tool was completed by parents at the initial 
encounter and again at 6 weeks. 
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Anticipated Project Impact 
The overall goal of this pilot project was to provide important instruction and education 
to parents of children with AD in hopes to reduce eczema severity.  The EAP and general 
information about eczema are important tools to help parents efficiently and confidently manage 
their child’s skincare with this regressive condition.  Managing eczema can be complicated.  
Increasing communication between the provider and parent may promote better outcomes for 
treatment, adherence of treatment regimens and improve quality of life for children who are 
affected by eczema.  The results of this project may have a potential impact on future research 
and projects allowing an evidence-based intervention such as the written EAP to become 
standardized nationally and worldwide.   
PICOT Question 
P: In a primary care clinic, pediatric patients ages 4 months to 17 years of age diagnosed with 
mild to moderate atopic dermatitis also known as eczema 
I: Provide parent/caregiver education using a written Eczema Action Plan (EAP) in addition to 
verbal teaching 
C: Compared to standard verbal teaching of eczema management 
O: Result in decreased severity of child eczema symptoms and increased parental self-efficacy  
T: Within 6 weeks-10 weeks 
EPB Model 
The Iowa Model was selected as the evidence-based practice model for this pilot project.  
It is a constant challenge for nurses to provide the highest quality care that is measurable and 
evidence-based.  If care is not evidence-based, a potential for patient harm may increase (Doody 
& Doody, 2011). The Iowa Model is an excellent framework to help engage the stakeholder and 
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pilot the written EAP systematically, then evaluate and adjust intervention accordingly.  The 
Iowa Model is knowledge focused as is the intervention and helped to individualize evidence-
based practice into this clinical setting.  Validity of evidence was variable.  The Iowa Model 
served as guide in the introduction, development and evaluation of evidence-based practice.  The 
model was used to evaluate if the EAP was appropriate for adoption by analysis of its structure, 
process, and outcome data in order to deliver the best clinical care.  Results will be disseminated 
and if sustainable, the Iowa Model can continuously guide a written EAP into multidisciplinary 
healthcare settings.   
Project Process Plan  
 A letter of support was obtained by the sole provider of the practice approving use of 
collected data and dissemination on April 20, 2018 (see Appendix I).  University of San Diego 
(USD) faculty approval was obtained April 24, 2018 (see Appendix J).   The USD Institutional 
Review Board approved an exempt status on April 27, 2018 (see Appendix K).    Data collection 
began on April 20, 2018 and the EAP was implemented by the DNP candidate.  A total of 30 
voluntary participants were enrolled in this pilot project.  The DNP candidate sent out electronic 
copies of the written EAP via text to participants between 1-2 weeks post EAP implementation 
and offered to answer any questions caregivers had regarding the EAP.  At about 6-7 weeks post 
intervention, participants were contacted via text message to complete the POEM and PASECI 
questionnaires.  Of the 30 participants, 22 completed the post-intervention POEM and PASECI 
via Google Forms.  Twenty-dollar gift cards to Walmart were mailed individually to participants 
who completed post intervention measurements.  Eight participants were lost to follow-up for 
unknown reasons.  Data collection concluded on August 1, 2018.  Data analysis was conducted 
between August 1, 2018 to August 22, 2018. 




A significant component of completing an evidence-based project is to share the results.  
The dissemination of project findings was presented to key stakeholders including the sole 
physician and the entire staff on January 30, 2019.  A successful poster presentation was 
conducted at the clinical site.  The poster included background, evidence for the clinical problem, 
purpose of the project, project plan, results of data analysis, conclusions, and implications for 
clinical practice. 
A second presentation took place on campus at the USD Project Presentation Day on 
February 28, 2019.  A PowerPoint presentation was created to present the pilot project and its 
findings to fellow students and faculty at the Hahn School of Nursing.  An exchange of questions 
and answers prompted interest and ideas of clinical implications and inspiration to upcoming and 
experienced practitioners. 
A third presentation took place at a national health conference in the form of a poster 
presentation.  This project was selected by The California Association for Nurse Practitioners 
42nd Annual Educational Conference that took place March 14-17, 2019 in San Diego, 
California.  The results of this pilot project were shared on a broader statewide and national level 
to healthcare providers who showed interest in integrating EAPs into their clinical practice. 
Sustainability 
It is important to consider how use of a written EAP will remain sustainable in this 
clinical practice.  The dissemination of results may motivate the provider and staff to continue 
utilization in order to provide best practice and positive long-term outcomes for patients and their 
families.  The physician and the clinic nurse could become champions to continue 
implementation.  Copies of written EAPs can be stored near other patient education handouts for 
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visibility and accessibility.  This practice is implementing an electronic medical record system in 
the near future.  An electronic prompt could be created as a reminder for the physician to use 
EAPs as an important tool to manage eczema.   
Additionally, satisfaction surveys could be distributed among participants of this study 
one year later that may reveal a higher patient satisfaction.  A good rapport was established 
between the physician and the DNP candidate throughout this project.  It is possible the DNP 
student continue and encourage sustainability with the practice every 6 months for the first-year 
post EBP project via casual face-to-face discussion or by text messaging to find out if any 
challenges arise with the EAP and provide suggestions for improvement.  All these elements 
combined will help successfully sustain the EAP long-term greater than 12 months. 
Results 
Caregivers reported a 9.8 comprehension level immediately following receipt of the EAP.    
Analysis of the data revealed improvement in eczema severity and caregiver self-efficacy.  
Eczema severity decreased from an average of 7.33 POEM points (mild to moderate severity) to 
an average of 2.55 points (clear to mild severity) post-intervention (see Figures 1 and 2).   Forty-
five and a half percent of the sample had no change in severity, 55% showed decreased change, 
and 4.5% had an increase in severity (see Figure 3).  
Caregiver self-efficacy improved from an average of 5.51 PASECI points to an average 
of 8.11 points post-intervention (see Figure 4).  There was improvement in 100% of seven 
measured PASECI categories.  Post-intervention, caregivers reported most confidence increase in 
how well they were able to appropriately use steroids with a 33.3% improvement, how well they 
were able to recognize infection with a 32.9% improvement, and how well they were able to 
manage eczema symptoms with a 27.5% improvement (see Figure 5).  There was a significant 
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correlation between the pre and post PASECI scores; 19.36% of a change in the post PASECI 
could be explained by the pre PASECI score (r = .441, p = .040), however statistical significance 
was underpowered by the sample size. 
Ninety percent of caregivers reported they had never utilized an EAP prior to this project. 
The majority of caregivers were 64% mothers and 27% fathers between the ages of 26 to 35 
years of age.  The primary languages reported were 44% English, 27% Vietnamese, and 60% 
percent of caregivers worked full-time.  Eighty percent of children were 5 years of age and 
younger with an equal distribution of male and females.  Fifty-three percent children were 
reported Hispanic and 23% were Asian.  Thirty-three percent had a family history of seasonal 
allergies, and 20% had a family history of asthma.  Forty percent had been diagnosed with 
eczema less than six months while 40% had been diagnosed for greater than a year.  Refer to 
Tables 1-10 for a more detailed description of the project demographics. 
Implications for Clinical Practice 
 The results of this pilot project support the beneficial use of written EAPs in primary care 
as presented by previous evidence.  Formatted and individualized EAPs are comprehensible and 
improve caregiver confidence and self-efficacy resulting in decreased severity of childhood 
eczema symptoms.  Demographic analysis and limitations of this project prove availability of 
translated EAPs and educational handouts may have increased impact if offered in a caregiver’s 
primary language.  As caregiver confidence levels increase, they feel more equipped to manage 
and care for childhood atopic dermatitis.  Lifelong maintenance including proper use of 
medications and avoidance of environmental triggers requires a standard approach clinicians can 
easily utilize in practice.  Dissemination of this small project may influence future evidence-
based projects and research of a larger scale in order to produce potential statistically significant 
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data and validation of a written EAP.  Future studies and projects may expand EAP utilization 
beyond pediatric primary care to other clinical or non-clinical environments.  Morover, family 
quality of life could be evaluated as well as long-term physiologic and psychologic outcomes of 
eczema patients. Further research and evidence may substantiate the use of a written EAP 
standardizing design and method to better equip caregivers in the lifelong maintenance and 
control of childhood atopic dermatitis.   
Cost-benefit Analysis 
Utilization of a written EAP in primary care is cost-effective.  A financial key benefit 
resulting from this project was treatment cost savings for families.   The total costs for this 
project was approximately $620 including $40 of purchased materials, $440 of participant 
incentives, and $140 for paper copies to create an EAP packet for each parent.  The average out 
of pocket expenses is approximately $274 per month for families who seek multiple over the 
counter treatments before seeing a provider (Filanovsky et al., 2016).  For patients who are not 
typically covered by health insurance, effective treatments include moisturizers and prescribed 
steroid creams.  This cost is approximately $100 per month (“How Much Does Eczema 
Treatment Cost?,” 2018).  Each patient would be able to save about $174 per month with correct 
and effective treatment as directed by use of the EAP.  For this project of 30 initial participants, 
$174 x 30 patients = $5220 eczema treatment costs per month.  Potential patient cost avoidance 
benefit was approximately $8.42 for every $1.00 spent on this project.  This was approximately a 
742% return on investment with use of an EAP in comparison to no EAP. 
Non-financial key benefits from this project included congruence of AAP clinical 
guidelines and best evidence-based clinical practice.  A reduction in eczema severity may 
potentially decrease the risk for infection, emergency department visits, and hospital admissions.  
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Additionally, the practice may benefit from EAP implementation with an increase in service 
availability for higher acuity conditions.  If eczema severity is unchanged or worsens, 
documented use of the EAP may help the provider improve identification for dermatology 
referrals.  Furthermore, caregivers may recognize the quality of individualized medical services 
received for their child generating positivity and loyalty to the practice.   
Limitations 
 This project included a recruitment of 30 voluntary participants, however due to 
contraints of the project, the potential quantity of contributors was limited due to different factors 
including language, small private practice, and timeline limitations.  Of 30 participants, 22 
completed the project.  Inclusion requirements to participate in the project were ability to speak, 
read, and write in English.  No translated versions of the EAP, patient education handouts, or 
instruments were offered.   Data analysis showed English was the primary language for 
approximately 44% of the sample followed dominantly by Vietnamese and Spanish.  Although 
many of the participants met inclusion criteria, some caregivers may have been unable to 
participate in follow-up asssessments due to English language barriers.  Time contraits of this 
project also contributed to the small size of the sample and was restricted due to academic time 
limitations.  Although monetary incentive was offered to participants to complete the follow-up 
surveys, it is unclear if the reward was deemed valuable to them.  Inability to use a smart phone 
to text and use Google Forms, change in contact information, forgetfulness, personal reason or 
choice to not participate in follow-up may have been additional factors explaining reasons for not 
completing the post survey. 
 
 




 Two of the three anticipated project outcomes were met.  The caregiver EAP 
comprehension goal was met with 9.8 of 10.  Eczema severity decreased by 4.78 out of 5 POEM 
points post intervention and indicates a successful outcome.  The caregiver self-confidence goal 
was met with an average of 8.11 of 10.  Atopic dermatitis affects an estimated 30% of the United 
States population with the majority including the pediatric population (“Eczema (Atopic 
Dermatitis) | NIH: National Institute of Allergy and Infectious Diseases,” 2018.).  There is 
currently no standardized tools used to manage eczema in the pediatric primary care setting.  
Literature has proven comprehensive caregiver education through use of a written EAP 
decreased symptom severity and improved caregiver self-efficacy.  Implementing EAPs in the 
primary pediatric care setting is a feasible practice which may successfully increase caregiver 
knowledge in managing eczema and reduce clinical symptoms.   
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Type Frequency % 
Mother 19 64% 
Father 8 27% 



























Age of Caregiver 
Age in years Frequency % 
18-25 2 7% 
26-35 21 70% 
36-45 4 13% 




















Primary Language of Caregiver 
Primary language Frequency % 
English 13 44% 
Vietnamese 8 27% 
Spanish 6 20% 
Azari 1 3% 
Lao 1 3% 





















Work Status of Caregivers 






























Age of Children 
Age Frequency % 
<6 months 5 17% 



























































Race of Children 
Race Frequency Approximate % 
White 1 3% 
Hispanic  16 53% 
Asian 7 23% 
Black 2 7% 
Asian Hispanic 1 3% 
White Hispanic 






















Child Allergy, Medical History, Exposure 
Type Frequency % 
Seasonal allergy  
(family history) 







Food allergy  
Asthma 
Asthma (family history) 





























Duration of Eczema Prior to EAP 
Time Frequency % 
<6 months 12 40% 
6-12 months 6 20% 






















History of Eczema Action Plan 
Type Frequency % 
History of using EAP 











Figure 1: Eczema severity decreased by 4.78 average POEM points post EAP.  This illustrates a 





























PRE-EAP                                                 POST-EAP
Average Eczema Severity Scores




Figure 2: Eczema severity ranged from clear to very severe pre-EAP and improved to clear to 
















Figure 3: More than half of caregivers reported a decrease in eczema symptoms and nearly half 















Figure 4: Parental self-efficacy increased by an average of 2.6 PASECI points post-EAP.  This 




































To be completed by parent/caregiver   
 
Please circle your answer 
 
1. Are you the caregiver of this child? 
 
Yes  No 
 
2. Who is filling out this form? 
 
Parent  Grandparent  Relative Guardian  
 
3. What is your age? 
 
Less than 18 years 18-25 years 26-35 years 36-45 years 46-65 years 
 
4. Is English your primary language? 
 
Yes  No If No, what is your primary language? ____________________ 
 
5. Do you work or attend school: 
 
Full-time  Part-time  Not currently working or attending school 
 




7. What is the sex of the child? 
 
Male  Female 
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8. What is the race of the child? 
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Appendix A (continued) 
 
 
Prefer not to answer 
 
9. Does the child have asthma? 
 
Yes  No 
 
10. Does the child have food allergies? 
 
Yes  No 
 
If Yes, what foods?________________________________________________ 
 
11. Is there any family history of: 
 
asthma food allergies  seasonal allergies none 
 
12.  Are there any smokers in the home where the child lives? 
 
Yes  No 
 
13. How long has your child had eczema? 
 
Less than 6 months  6-12 months  more than a year 
 
14. Have you ever received an Eczema Action Plan before? 
 









Patient-Oriented Eczema Measure for Children 
 
POEM (Patient-Oriented Eczema Measure)- for proxy completion by caregiver 
 
Please circle one response for each of the seven questions below about your child’s eczema.  If 
your child is old enough to understand the question then please fill in the questionnaire 
together.  Please leave blank any questions you feel unable to answer. 
 
 
1. Over the last week, on how many days has your child’s skin been itchy because of their 
eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
2. Over the last week, on how many nights has your child’s sleep been disturbed because of 
their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
3. Over the last week, on how many days has your child’s skin been bleeding because of their 
eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
4. Over the last week, on how many days has your child’s skin been weeping or oozing clear 
fluid because of their eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
5. Over the last week, on how many days has your child’s skin been cracked because of their 
eczema? 




No days 1-2 days 3-4 days 5-6 days Every day 
 
6. Over the last week, on how many days has your child’s skin been flaking off because of their 
eczema? 
 
No days 1-2 days 3-4 days 5-6 days Every day 
 
7. Over the last week, on how many days has your child’s skin felt dry or rough because of their 
eczema? 
 





















Parental Self-Efficacy with Eczema Care Index 
 
MANAGING MEDICATION/ECZEMA AND SYMPTOMS: How CONFIDENT do you feel that you can: 
 
1. Choose a moisturizer (grease) that is suitable for your child _____ 
0    1    2  3   4    5    6   7   8    9    10 
Cannot do       Highly certain can do 
2. Successfully apply moisturizers (grease) to your child’s eczema  _____ 
0    1    2  3   4    5    6   7   8    9    10 
Cannot do       Highly certain can do 
3. Correctly use steroid creams for your child _____ 
0    1    2  3   4    5    6   7   8    9    10 
Cannot do       Highly certain can do 
4. Make the right choice of medication if the symptoms of your child’s eczema become worse _____ 
0    1    2  3   4    5    6   7   8    9    10 
Cannot do       Highly certain can do 
5. Manage to avoid things that irritate/aggravate your child’s eczema _____ 
0    1    2  3   4    5    6   7   8    9    10 
Cannot do       Highly certain can do 
6. Manage your child’s eczema so that his/her symptoms are under control _____ 
0    1    2  3   4    5    6   7   8    9    10 
Cannot do       Highly certain can do 
7. Know what to do if you think your child’s eczema has become infected _____ 
0    1    2  3   4    5    6   7   8    9    10 
Cannot do       Highly certain can do 
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How products qualify for the 
NEA Seal of Acceptance™ 
Manufacturers submit product ingredient informa- 
tion, formulation data, and testing results (sensitivity, 
safety and toxicity) for scientific review by the Na- 
tional Eczema Association. Products eligible for the 
NEA Seal of Acceptance™ are those that have been 
created or intended for use by people with eczema 
or sensitive skin. The Seal of Acceptance Review 
Panel consists of experts in dermatology, allergy and 
pediatrics. 
The NEA Seal of Acceptance™ program evaluates 
products in the following categories: 
l Personal Care Products 
l OTC Drugs 
l Household Products 
l Fabric Products 
 
The NEA Seal of Acceptance™ 
Product Directory 
The Product Directory contains a listing of products 
that have received the NEA Seal of Acceptance™. 
Further information about Seal of Acceptance 
products can be found on the NEA website. 
Personal Care Products 
The importance of proper bathing and moisturizing 
practices cannot be over-emphasized as a treatment 
for eczema and sensitive skin. Use of mild, fragrance 
free, low-pH cleansers are best. Moisturizers maintain 
skin hydration and barrier function. Generic petroleum 
jelly and mineral oil (without additives) are two of 
the most effective moisturizing products. 
MOISTURIZERS 
l AVEENO® Baby Eczema Therapy Moisturizing Cream 













l Gold Bond® Ultimate Eczema Relief Lotion 
l MD Moms® Baby Silk Daily Skin Protection Moisturizing Balm 
l MD Moms® Baby Silk Daily Skin Protection Moisturizing Balm 
— unfragranced 
l MD Moms® Baby Silk Dry Skin Rescue Extreme Care Cream 
— unfragranced 
l Mustela® Dermo-Pediatrics Stelatopia® Lipid-Replenishing Balm 
l Mustela® Dermo-Pediatrics Stelatopia® Milky Bath Oil 
l Mustela® Dermo-Pediatrics Stelatopia® Moisturizing Cream 
l NEOSPORIN® ECZEMA ESSENTIALS™ Daily Moisturizing Cream 
l  Neutrogena® Norwegian Formula® Hand Cream 
l Neutrogena® Oil-Free Moisture for Sensitive Skin 
l Remarle® Shea Butter Crème 
l Theraplex® ClearLotion® 
l Theraplex® Eczema Therapy 
l Theraplex® Emollient 
l Triple Cream® 
l Vaseline® 100% Pure Petroleum Jelly 
l Vanicream™ Lite Lotion 
l Vanicream™ Skin Cream 
l Vaniply™ Ointment 
l Weleda White Mallow Face Cream 
l Weleda White Mallow Body Lotion 
 
CLEANSERS 















l Exederm™ Baby Shampoo 
l MD Moms® Baby Silk Gentle All-Over Clean Hair & Body Wash 
l MD Moms® Baby Silk Gentle All-Over Clean Hair & Body Wash 
- unfragranced 
l Exederm™ Conditioner 
l Exederm™ Shampoo 
OTC Drugs 
Over-the-counter (OTC) medicines are drugs you 
can buy without a prescription. It is important to 
take medicines correctly, and be careful when giving 
them to children. More medicine does not necessarily 
mean better. You should never take OTC medicines 
longer or in higher doses than the label recommends. 
If your symptoms don’t go away, it’s a clear signal 
that it’s time to see your healthcare provider. 
OTC drugs containing hydrocortisone require 
special care. 
l Cortizone-10® Hydratensive™ Eczema Lotion 
l Cortizone-10® Intensive Healing Lotion Eczema 
l Exederm™ Flare Control Cream 
l NEOSPORIN® ECZEMA ESSENTIALS™ 
Hydrocortisone Anti-Itch Cream 
Household Products 
Products accepted by NEA avoid certain chemicals, 
dyes, perfumes, and residues that can irritate eczema 
and sensitive skin. 
l ̀ all® FREE CLEAR Laundry Detergent 
Fabric Products 
Certain clothing, linens, and other fabric products can 
be beneficial for those with eczema or sensitive skin. 
l AD RescueWear wet wrap therapy garments 
l DermaTherapy® Pillow Cases 
l DermaTherapy® Sheets 
l HALO® ComfortLuxe™ Sensitive Skin Sleepwear 
  nationaleczema.org 
l Dove® DermaSeries Extreme Dryness Relief Intense Repairing l Exederm™ Body Wash 
 Body Eczema Therapy Cream l Kiss of Nature Oh My Baby!! Fragrance Free Moisturizing Body Bar 
l Dove® DermaSeries Extreme Dryness Relief Intense Repairing l Kiss of Nature Oh My Sassy Baby!! Fragrance Free 
 Body Cream  Moisturizing Body Bar with Goat Milk 
l Exederm™ Baby Lotion l Kiss of Nature Oh My Baby!! Fragrance Free Liquid Castile 
l Exederm™ Baby Moisturizer  Hand Soap 
l Exederm™ Baby Oil l MD Moms® Baby Silk Gentle All-Over Cleansing Towelettes 
l Exederm™ Body Lotion  — unfragranced 
l Exederm™ Body Oil l MD Moms® Baby Silk Gentle All-Over Cleansing Towelettes 
l Exederm™ Intensive Moisture Cream l Mustela® Dermo-Pediatrics Stelatopia® Cream Cleanser 
l Hydrolatum® l NEOSPORIN® MOISTURE ESSENTIALS™ Daily Body Wash 
l Glaxal Base® Everyday Moisturizing Lotion l Neutrogena® Ultra Gentle Hydrating Cleanser 
l Glaxal Base® Moisturizing Cream   
 
l AVEENO® Eczema Therapy Bath Treatment l AVEENO® Baby Cleansing Therapy Moisturizing Wash 
l AVEENO® Eczema Therapy Moisturizing Cream l Avène TriXéra+ Selectiose® Emollient Cleansing Gel 
l Avène TriXéra+ Selectiose® Emollient Cream l Avène TriXéra+ Selectiose® Emollient Cleansing Bath 
l Baby Pibu™ Baby Butter l Baby Pibu™ Bathtime Wash 
l Baby Pibu™ Hydrating Ointment l CeraVe® Hydrating Cleanser 
l BabySpa® Natural Relief Eczema Cream l Cetaphil® RESTORADERM® Skin Restoring Body Wash 
l CapriClear® l CLn® BodyWash 
l CeraVe® Moisturizing Cream l CLn® Facial Cleanser 
l CeraVe® Moisturizing Lotion l CLn® SportWash 
l CeraVe® Renewing SA Cream l Dove® DermaSeries Extreme Dryness Relief Ultra Caring 
l CeraVe® SA Renewing Lotion  Gentle Body Cleanser 
l CeraVe® SA Therapeutic Hand Cream l Dove® DermaSeries Extreme Dryness Relief Ultra Caring 
l Cetaphil® RESTORADERM® Skin Restoring Moisturizer  Gentle Cream Face Cleanser 
l Curél® Itch Defense® Lotion l Dove® DermaSeries Extreme Dryness Relief Ultra Caring 
l Dove® DermaSeries Extreme Dryness Relief Intense Repairing  Gentle Cleansing Bar 
 Rough Patch Treatment l Exederm™ Baby Bath 
 




Caregiver’s Comprehension of Eczema Action Plan 
1. How well do you understand your child’s Eczema Action Plan? Circle a number. 
 
 
0    1    2  3   4    5    6   7   8    9    10  
 

































Thank you for participating in this important pilot project to manage childhood eczema.  I 
would like to find out how well the Eczema Action Plan works for you and your child in 6 weeks.  
 
Please indicate how you would like to return 2 forms: 
 
• POEM (Patient-Oriented Eczema Measure) 
• Parental Self-Efficacy with Eczema Care Index 
 
Take a picture of the forms and text to (XXX) XXX-XXXX. 
 
 
Phone call.   Best time to call________________________________________________ 
 
 
Please e-mail forms to XXXXXXXXXXXXXXX.   
 
As an appreciation for your participation, I would like to offer you a $20 gift card to Walmart at 
the completion of the study.  Please provide your contact information which will remain private 


















RETURN FORMS BY 
 
__________________ 
 
